IDDF2019-ABS-0246 LncRNA XIST Regulated Chemotherapeutic Sensitivity of Mir-125B-2–3p by Targeting Wee1 in Colorectal Cancer

Zhao-lei Zeng,Jia-huan Lu,Yun Wang,Ying Wang,Zhan-hong Chen,Dong-dong Yang
DOI: https://doi.org/10.1136/gutjnl-2019-iddfabstracts.48
2019-01-01
Abstract:Background Accumulating evidence has demonstrated that microRNAs regulate diverse tumorigenic processes, and play important roles in tumor metastasis and growth. Recently, miR-125b-2-3p was identified as a meaningful prognosis factor predicting the chemotherapeutic sensitivity in advanced colorectal cancer (CRC). However, the biological function and molecular mechanism of miR-125b-2-3p in chemotherapy of advanced CRC are urgent to explain. Methods MiR-125b-2-3p expression was detected by real-time PCR (RT-PCR) in CRC tissues. The gain-of-function experiments were performed to assess the effect of miR-125b-2-3p on CRC growth, metastasis, invasion and drug sensitivity in vitro and in vivo. The prediction of the database has determined the competitive endogenous RNAs (ceRNAs) and target gene, which has confirmed by bioinformatic analysis, luciferase reporter assays, rescue experiments and western blot assays. Results MiR-125b-2-3p expression was significantly downregulated in CRC tissues and cell lines. The high expression of miR-125b-2-3p was correlated with lower growth ability and metastasis. In addition, miR-125b-2-3p overexpression remarkably improves the chemotherapeutic sensitivity in vitro and in vivo. Mechanistically, miR-125b-2-3p was regulated by competitive endogenous RNAs, LncRNA-XIST, and influenced the expression of WEE1 G2 checkpoint kinase (WEE1). Upregulation of miR-125b-2-3p would reverse CRC growth and EMT process caused by LncRNA XIST by rescue analysis. Conclusions Low expression of miR-125b-2-3p in CRC was linked to lower chemotherapeutic sensitivity and poor survival. LncRNA XIST would promote CRC invasion and migration by functioning as a ceRNA for miR-125b-2-3p to mediate WEE1 expression. Our finding suggested that miR-125b-2-3p may serve as a potential marker of chemotherapeutic sensitivity in CRC patients.
What problem does this paper attempt to address?